{"id":"cisplatin-vindesine-mmc-concurrent-radiation","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Esophagitis"},{"rate":null,"effect":"Pneumonitis"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Peripheral neuropathy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin is a platinum-based alkylating agent that cross-links DNA; vindesine is a vinca alkaloid that disrupts microtubule formation during mitosis; and mitomycin C is an antibiotic that alkylates DNA. When combined with concurrent radiation therapy, these agents work synergistically to maximize tumor cell death in locally advanced cancers.","oneSentence":"This combination uses three chemotherapy agents (cisplatin, vindesine, and mitomycin C) alongside radiation therapy to damage cancer cell DNA and inhibit cell division through multiple mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:06.292Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Locally advanced non-small cell lung cancer (concurrent chemoradiation)"}]},"trialDetails":[{"nctId":"NCT00144053","phase":"PHASE3","title":"A Phase Ⅲ Randomized Study of Mitomycin/Vindesine/Cisplatin Versus Irinotecan/Carboplatin Versus Paclitaxel/Carboplatin With Concurrent Thoracic Radiotherapy for Unresectable Stage Ⅲ Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"West Japan Thoracic Oncology Group","startDate":"2001-04","conditions":"Lung Cancer","enrollment":450}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":753,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cisplatin+Vindesine+MMC/ concurrent radiation","genericName":"Cisplatin+Vindesine+MMC/ concurrent radiation","companyName":"West Japan Thoracic Oncology Group","companyId":"west-japan-thoracic-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses three chemotherapy agents (cisplatin, vindesine, and mitomycin C) alongside radiation therapy to damage cancer cell DNA and inhibit cell division through multiple mechanisms. Used for Locally advanced non-small cell lung cancer (concurrent chemoradiation).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}